El.En. S.p.A. (IT:ELN)
:ELN
Top Page
El.En. S.p.A.
(ELN)
Select Model
Select Model
Rating:61Neutral
Price Target:
€13.00
▼(-0.61% Downside)
Action:ReiteratedDate:04/08/26
The score is supported primarily by solid financial performance (especially low leverage and a strengthening cash-flow profile), but is held back by weak technical signals (negative MACD and trading below key moving averages) and a valuation that is only average given the P/E and modest dividend yield.
Positive Factors
Balance sheet strength
Very low leverage and declining debt-to-equity (~0.09 in 2025) give the company durable financial flexibility. This supports capital spending, R&D and acquisition optionality, and cushions cyclical demand swings without forcing asset sales or aggressive financing.
Negative Factors
Gross-margin compression
Sharp gross-margin compression in the latest year signals pressure on core profitability drivers—pricing, product mix or input costs. If sustained, this erodes operating leverage, reduces cash available for reinvestment, and pressures long-term return on capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and declining debt-to-equity (~0.09 in 2025) give the company durable financial flexibility. This supports capital spending, R&D and acquisition optionality, and cushions cyclical demand swings without forcing asset sales or aggressive financing.
Read all positive factors
El.En. S.p.A. (ELN) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€1.05B
Dividend Yield1.58%
Average Volume (3M)100.73K
Price to Earnings (P/E)10.9
Beta (1Y)0.90
Revenue Growth-18.41%
EPS Growth-15.30%
CountryIT
Employees2,080
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.32
Shares Outstanding80,384,550
10 Day Avg. Volume100,375
30 Day Avg. Volume100,726
Financial Highlights & Ratios
PEG Ratio-1.64
Price to Book (P/B)2.71
Price to Sales (P/S)1.89
P/FCF Ratio18.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.90Price Target Upside13.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.75
Revenue Forecast (FY)€627.48M
El.En. S.p.A. Business Overview & Revenue Model
Company Description
EL.En. S.p.A. engages in the research and development, manufacture, distribution, and sale of laser systems in Europe and internationally. The company offers medical laser equipment for use in the fields of physiotherapy, orthopedics, traumatology...
How the Company Makes Money
El.En. makes money mainly by selling laser equipment and associated solutions to customers in its medical and industrial markets, complemented by recurring and service-related revenues tied to the installed base.
1) Equipment and system sales (pr...
El.En. S.p.A. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
84
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 590.85M | 565.85M | 692.29M | 673.58M | 571.40M |
| Gross Profit | 131.62M | 238.80M | 252.08M | 243.47M | 206.09M |
| EBITDA | 92.83M | 97.35M | 83.94M | 90.71M | 76.59M |
| Net Income | 43.41M | 51.61M | 48.24M | 55.11M | 45.44M |
Balance Sheet | |||||
| Total Assets | 627.88M | 740.72M | 719.21M | 735.89M | 650.69M |
| Cash, Cash Equivalents and Short-Term Investments | 211.44M | 157.49M | 135.36M | 165.13M | 182.45M |
| Total Debt | 38.07M | 46.72M | 73.63M | 82.92M | 60.50M |
| Total Liabilities | 200.41M | 329.92M | 343.75M | 379.25M | 362.99M |
| Stockholders Equity | 411.72M | 385.02M | 346.03M | 313.19M | 269.37M |
Cash Flow | |||||
| Free Cash Flow | 60.08M | 73.61M | -1.14M | -16.31M | 63.35M |
| Operating Cash Flow | 70.81M | 83.07M | 12.22M | 2.12M | 79.48M |
| Investing Cash Flow | -12.97M | 68.68K | -16.97M | -30.15M | -20.23M |
| Financing Cash Flow | -30.70M | -47.99M | -24.79M | 10.25M | -3.51M |
El.En. S.p.A. Technical Analysis
Positive
13.08
Price Trends
13.25
Negative
13.29
Negative
12.42
Positive
Market Momentum
-0.13
Negative
56.91
Neutral
73.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:ELN, the sentiment is Positive. The current price of 13.08 is above the 20-day moving average (MA) of 12.28, below the 50-day MA of 13.25, and above the 200-day MA of 12.42, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 56.91 is Neutral, neither overbought nor oversold. The STOCH value of 73.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:ELN.
El.En. S.p.A. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | €10.08B | 22.48 | 21.26% | 2.67% | 12.58% | -4.34% | |
61 Neutral | €1.05B | 10.94 | 15.29% | 1.58% | -18.41% | -15.30% | |
56 Neutral | €3.30B | 25.59 | 12.16% | 1.80% | 4.69% | 15.79% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €476.99M | 28.48 | ― | 5.24% | 11.25% | -76.44% |
* General Sector Average
IT:ELN
El.En. S.p.A.
13.08
5.36
69.45%
IT:DIA
DiaSorin S.p.A.
61.10
-33.77
-35.59%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
48.84
2.40
5.18%
IT:GHC
Garofalo Health Care S.P.A.
4.75
-0.29
-5.68%
IT:GPI
GPI SpA
16.56
8.42
103.44%
IT:IMD
I.M.D. International Medical Devices S.P.A.
1.37
0.05
3.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.